Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis

Authors

Shanthi Narla, Department of Dermatology, St. Luke's University Health Network, Easton, Pennsylvania, USA.
Jonathan I. Silverberg, Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.

Document Type

Journal Article

Publication Date

2-17-2023

Journal

Dermatitis : contact, atopic, occupational, drug

DOI

10.1089/derm.2022.29004.sna

Abstract

Multiple Janus Kinase (JAK) inhibitors were developed as potential treatments for moderate-to-severe atopic dermatitis (AD). There is a substantial amount of safety data from recent trials of oral JAK inhibitors in patients with AD. However, the vast majority of safety data for oral JAK inhibitors is derived from patients with rheumatoid arthritis and other immune-mediated disorders, and is primarily derived from tofacitinib, a pan-selective JAK inhibitor. This narrative review examines safety data for oral JAK inhibitors from studies in AD and other indications. The available data do demonstrate that rare but serious and life-threatening adverse events can occur with oral JAK inhibitor treatment and should be carefully considered in therapeutic shared decision making.

APA Citation

Narla, Shanthi and Silverberg, Jonathan I., "Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis" (2023). GW Authored Works. Paper 2388.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/2388

Department

Dermatology